CN1668306A - 用于治疗与突变的 r e t激酶相关疾病的4－(4－甲基哌嗪－1－基甲基)－n－[4－甲基－3－((吡啶－3－基)嘧啶－2－基基氨)苯基］－苯甲酰胺 - Google Patents

用于治疗与突变的 r e t激酶相关疾病的4－(4－甲基哌嗪－1－基甲基)－n－[4－甲基－3－((吡啶－3－基)嘧啶－2－基基氨)苯基］－苯甲酰胺 Download PDF

Info

Publication number
CN1668306A
CN1668306A CNA038173344A CN03817334A CN1668306A CN 1668306 A CN1668306 A CN 1668306A CN A038173344 A CNA038173344 A CN A038173344A CN 03817334 A CN03817334 A CN 03817334A CN 1668306 A CN1668306 A CN 1668306A
Authority
CN
China
Prior art keywords
methyl
ylmethyl
pyridin
ret
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038173344A
Other languages
English (en)
Chinese (zh)
Inventor
J·A·费金
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Cincinnati
Original Assignee
University of Cincinnati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Cincinnati filed Critical University of Cincinnati
Publication of CN1668306A publication Critical patent/CN1668306A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA038173344A 2002-07-24 2003-05-23 用于治疗与突变的 r e t激酶相关疾病的4－(4－甲基哌嗪－1－基甲基)－n－[4－甲基－3－((吡啶－3－基)嘧啶－2－基基氨)苯基］－苯甲酰胺 Pending CN1668306A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39840902P 2002-07-24 2002-07-24
US60/398,409 2002-07-24

Publications (1)

Publication Number Publication Date
CN1668306A true CN1668306A (zh) 2005-09-14

Family

ID=30771216

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038173344A Pending CN1668306A (zh) 2002-07-24 2003-05-23 用于治疗与突变的 r e t激酶相关疾病的4－(4－甲基哌嗪－1－基甲基)－n－[4－甲基－3－((吡啶－3－基)嘧啶－2－基基氨)苯基］－苯甲酰胺

Country Status (8)

Country Link
US (2) US20060116381A1 (enExample)
EP (1) EP1526854A1 (enExample)
JP (1) JP2005535675A (enExample)
CN (1) CN1668306A (enExample)
AU (1) AU2003232960A1 (enExample)
BR (1) BR0312873A (enExample)
CA (1) CA2493000A1 (enExample)
WO (1) WO2004009087A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108473468A (zh) * 2015-11-02 2018-08-31 蓝图药品公司 Ret的抑制剂
CN112574201A (zh) * 2019-09-29 2021-03-30 四川科伦博泰生物医药股份有限公司 芳基胺类化合物、包含其的药物组合物及其制备方法和用途

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1899616A (zh) * 2006-07-20 2007-01-24 中国人民解放军军事医学科学院生物工程研究所 非受体酪氨酸激酶c－Abl特异性抑制剂的新用途
EP2918588B1 (en) 2010-05-20 2017-05-03 Array Biopharma, Inc. Macrocyclic compounds as TRK kinase inhibitors
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
DK3322706T3 (da) 2015-07-16 2021-02-01 Array Biopharma Inc Substituerede pyrazolo[1,5-a]pyridin-forbindelser som ret-kinaseinhibitorer
AR107912A1 (es) 2016-03-17 2018-06-28 Blueprint Medicines Corp Inhibidores de ret
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
WO2018022761A1 (en) 2016-07-27 2018-02-01 Blueprint Medicines Corporation Substituted cyclopentane-amides for treating disorders related to ret
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
CA3049136C (en) 2017-01-18 2022-06-14 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
WO2019143994A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
CA3087578C (en) 2018-01-18 2023-08-08 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
CA3087354C (en) 2018-01-18 2023-01-03 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CA3096043A1 (en) 2018-04-03 2019-10-10 Blueprint Medicines Corporation Ret inhibitor for use in treating cancer having a ret alteration
CN112996794A (zh) 2018-09-10 2021-06-18 阿雷生物药品公司 作为ret激酶抑制剂的稠合杂环化合物
KR20230017234A (ko) 2020-05-29 2023-02-03 블루프린트 메디신즈 코포레이션 프랄세티닙의 고체 형태

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543520A (en) * 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108473468A (zh) * 2015-11-02 2018-08-31 蓝图药品公司 Ret的抑制剂
CN112574201A (zh) * 2019-09-29 2021-03-30 四川科伦博泰生物医药股份有限公司 芳基胺类化合物、包含其的药物组合物及其制备方法和用途
CN112574201B (zh) * 2019-09-29 2024-04-19 四川科伦博泰生物医药股份有限公司 芳基胺类化合物、包含其的药物组合物及其制备方法和用途

Also Published As

Publication number Publication date
AU2003232960A1 (en) 2004-02-09
JP2005535675A (ja) 2005-11-24
WO2004009087A1 (en) 2004-01-29
EP1526854A1 (en) 2005-05-04
US20060116381A1 (en) 2006-06-01
US20070265274A1 (en) 2007-11-15
BR0312873A (pt) 2005-06-28
CA2493000A1 (en) 2004-01-29

Similar Documents

Publication Publication Date Title
CN1668306A (zh) 用于治疗与突变的 r e t激酶相关疾病的4－(4－甲基哌嗪－1－基甲基)－n－[4－甲基－3－((吡啶－3－基)嘧啶－2－基基氨)苯基］－苯甲酰胺
Wang et al. Medulloblastoma: from molecular subgroups to molecular targeted therapies
JP2005531488A (ja) 甲状腺癌を処置するためのｅｇｆ受容体阻害剤
EP3606525B1 (en) Compositions for treating aging-associated impairments using ccr3-inhibitors
JP2009514954A (ja) Ｔｒｐｖ３機能を変調するための化合物
CN104761544A (zh) Egfr酪氨酸激酶的临床重要突变体的选择性抑制剂
Susa et al. Tyrosine kinase src inhibitors: potential therapeutic applications
CN102414211A (zh) 3-([1,2,3]三唑-4-基)吡咯并[2,3-b]吡啶衍生物
CN107708698A (zh) 一种egfr/her2受体酪氨酸激酶抑制剂在制备治疗her2突变癌症药物中的用途
CN110507654A (zh) 有酪氨酸激酶抑制剂的组合产品和其应用
Wang et al. RET fusion in advanced non-small-cell lung cancer and response to cabozantinib: a case report
Prinz et al. Acid secretion and the H, K ATPase of stomach
Akram et al. Therapeutic uses of HSP90 inhibitors in non-small cell lung carcinoma (NSCLC)
JP2022502408A (ja) 妊娠中のｆｇｆｒ３関連骨疾患の処置ためのインフィグラチニブ
JP2017521468A (ja) 組み合わせ療法
CN107296807A (zh) Malt1靶向抑制物在制备malt1依赖性肿瘤治疗药物中的应用
TW201004621A (en) Substituted benzimidazoles for neurofibromatosis
Kim Molecular pathogenesis and targeted therapies in well-differentiated thyroid carcinoma
CN102665716A (zh) 用于治疗唐氏综合征的方法和药物组合物
PT1553950E (pt) Tratamento terapêutico
KR102023748B1 (ko) 순수한 5-ht6 수용체 길항제 및 nmda 수용체 길항제의 조합물
Guan et al. The activation of gastric inhibitory peptide/gastric inhibitory peptide receptor axis via sonic hedgehog signaling promotes the bridging of gapped nerves in sciatic nerve injury
US20200347136A1 (en) Constrained cyclic peptides as inhibitors of the cd2:cd58 protein-protein interaction for treatment of diseases and autoimmune disorders
JP2007505859A (ja) イマチニブおよびミドスタウリンでの消化管間質腫瘍の処置
US20050159426A1 (en) Treatment of neuroblastoma

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned
C20 Patent right or utility model deemed to be abandoned or is abandoned